The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 11, 2009, Pages 1016-1025

  Varas Lorenzo, Cristina ^a,e   Castellsague, Jordi ^a,e   Stang, Mary Rose ^b   Perez Gutthann, Susana ^a,e   Aguado, Jaume ^c   Rodriguez, Luis Alberto García ^d  

^a PFIZER INC   (United States)

^b Saskatchewan Ministry of Health   (Canada)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Department of Pharmacoepidemiology   (Spain)

^e RTI HEALTH SOLUTIONS   (United States)

Author keywords

Cohort study; Coxibs; Myocardial infarction; NSAIDs

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SASKATCHEWAN; TIME FACTORS;

EID: 70549111717     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1815     Document Type: Article

References (29)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl J Med 2000; 343: 1520-1528. (Pubitemid 30844348)
2. Kearney PM, Baignent C, Godwin J, Halls H, Emerson JR. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332: 1302-1308. (Pubitemid 44365384)
3. Hernandez-Diaz S, Varas-Lorenzo C, Rodriguez LAG. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266-274.
4. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase - A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA 2006; 296: 1633-1644. (Pubitemid 44511610)
5. Downey W, Stang MR, Beck P, Osei W, Nichol JL. Health services databases in Saskatchewan. In Pharmacoepidemiology. John Wiley & Sons, Ltd. Hoboken, NJ; USA: 2005; 295-310.
6. Rawson NSB, D'Arcy CA. Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan. Pharmacoepidemiol Drug Saf 1998; 7: 389-398.
7. Rawson NSB, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995; 14: 2627-2643. (Pubitemid 26014254)
8. The Nova Scotia-Saskatchewan Cardiovascular Disease Epidemiology Group. Estimation of the incidence of acute myocardial infarction using record linkage: a feasibility study in Nova Scotia and Saskatchewan. Can J Public Health 1989; 80: 412-4137.
9. The Nova Scotia-Saskatchewan Cardiovascular Disease Epidemiology Group. Trends in incidence and mortality from acute myocardial infarction in Nova Scotia and Saskatchewan 1974 to 1985. Can J Cardiol 1992; 8: 253-258.
10. Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154: 1598-1602.
11. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513.
12. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. A statement from the AHA Council on Epidemilogy and Prevention; AHA Statistics Committee World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003; 108: 2543-2549.
13. Braunwald E. Unstable angina. A classification. Circulation 1989; 80: 410-414.
14. Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J. Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital Automated Database. Pharmacoepidemiol Drug Saf 2008; 17(8): 842-852.
15. Version 9.1 of the SAS System for Windows. Copyright © 2003 SAS Institute Inc. Cary NC, USA.
16. International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology Practices (GPP). Pharmacoepidemiol Drug Saf 2005; 14: 589-595.
17. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis is Rheum 2000; 43(9): 1905-1915. (Pubitemid 30953253)
18. Therapeutic Guidelines: Analgesic Writing Group. Therapeutic Guidelines: Analgesic. Melbourne: Therapeutic Guidelines Ltd; 2002.
19. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-3006. (Pubitemid 38808323)
20. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
21. Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002; 54: 327-332. (Pubitemid 35056578)
22. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-1104. (Pubitemid 34522394)
23. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. Br Med J 2005; 330: 1366. (Pubitemid 40839565)
24. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-4481. (Pubitemid 40215729)
25. Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclooxygenase- 2 inhibitors in patients with a previous myocardial infarction. Heart 2007; 93: 189-194. (Pubitemid 46180292)
26. Pharand CH, Ackman ML, Jackevicius CA, Paradiso-Hardy FL, Pearson GJ. Use of OTC and herbal products in patients with cardiovascular disease. Ann Pharmacother 2003; 37: 899-904.
27. Strom BL. Pharmacoepidemiology. JohnWiley & Sons, Ltd. Hoboken, NJ, USA: 2005: 910.
28. West SL, Richter A, Melfi CA, McNutt M, Nennstiel ME, Mauskopf JA. Assessing the Saskatchewan database for outcomes research studies of depression and its treatment. J Clin Epidemiol 2000; 53: 823-831. (Pubitemid 30609647)
29. Tricco AC, Pham B, Rawson NS. Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions. J Clin Epidemiol 2008; 61: 192-197.